Literature DB >> 26994062

The Epidemiology of Herpes Zoster After Varicella Immunization Under Different Biological Hypotheses: Perspectives From Mathematical Modeling.

Giorgio Guzzetta, Piero Poletti, Stefano Merler, Piero Manfredi.   

Abstract

The impact of varicella vaccination on the epidemiology of herpes zoster (HZ) critically depends on the mechanism of immunological boosting, through which reexposures to varicella-zoster virus are thought to reduce the individual risk of HZ development. However, the qualitative and quantitative dynamics of this process are largely unknown. Consequently, mathematical models evaluating immunization strategies need to rely on theoretical assumptions. Available varicella-zoster virus models can be classified in 3 main families according to the postulated effect of exogenous boosting: 1) progressive accumulation of immunity following repeated reexposures; 2) partial protection that wanes over time; or 3) full but temporary immunity against HZ. In this work, we review and compare quantitative predictions from the 3 modeling approaches regarding the effect of varicella immunization on HZ. All models predict a qualitatively similar, but quantitatively heterogeneous, transient increase of HZ incidence. In particular, novel estimates from the progressive immunity model predict the largest increase in natural HZ and the largest incidence of HZ cases from reactivation of the vaccine strain, which in the long term will likely outnumber prevaccination numbers. Our results reinforce the idea that a better understanding of HZ pathogenesis is required before further mass varicella immunization programs are set out.
© The Author 2016. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  chickenpox; exogenous boosting; herpes zoster; progressive immunity; varicella immunization; varicella-zoster virus

Mesh:

Substances:

Year:  2016        PMID: 26994062      PMCID: PMC4832050          DOI: 10.1093/aje/kwv240

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  43 in total

1.  Herpes zoster: Burden of disease in France.

Authors:  S Gonzalez Chiappe; M Sarazin; C Turbelin; A Lasserre; C Pelat; I Bonmarin; O Chosidow; T Blanchon; T Hanslik
Journal:  Vaccine       Date:  2010-10-12       Impact factor: 3.641

2.  Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles.

Authors:  M C Schuette; H W Hethcote
Journal:  Bull Math Biol       Date:  1999-11       Impact factor: 1.758

Review 3.  Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review.

Authors:  T Panagiotopoulos; I Antoniadou; E Valassi-Adam
Journal:  BMJ       Date:  1999-12-04

4.  Hope-Simpson's progressive immunity hypothesis as a possible explanation for herpes zoster incidence data.

Authors:  Giorgio Guzzetta; Piero Poletti; Emanuele Del Fava; Marco Ajelli; Gian Paolo Scalia Tomba; Stefano Merler; Piero Manfredi
Journal:  Am J Epidemiol       Date:  2013-04-01       Impact factor: 4.897

5.  Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study.

Authors:  Sara L Thomas; Jeremy G Wheeler; Andrew J Hall
Journal:  Lancet       Date:  2002-08-31       Impact factor: 79.321

6.  Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study.

Authors:  Leonardo Emberti Gialloreti; Monica Merito; Patrizio Pezzotti; Luigi Naldi; Antonio Gatti; Maud Beillat; Laurence Serradell; Rafaelle di Marzo; Antonio Volpi
Journal:  BMC Infect Dis       Date:  2010-08-03       Impact factor: 3.090

7.  The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination.

Authors:  Rachel Civen; Sandra S Chaves; Aisha Jumaan; Han Wu; Laurene Mascola; Paul Gargiullo; Jane F Seward
Journal:  Pediatr Infect Dis J       Date:  2009-11       Impact factor: 2.129

8.  Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox.

Authors:  M Brisson; N J Gay; W J Edmunds; N J Andrews
Journal:  Vaccine       Date:  2002-06-07       Impact factor: 3.641

9.  The impact of demographic changes on the epidemiology of herpes zoster: Spain as a case study.

Authors:  Valentina Marziano; Piero Poletti; Giorgio Guzzetta; Marco Ajelli; Piero Manfredi; Stefano Merler
Journal:  Proc Biol Sci       Date:  2015-04-07       Impact factor: 5.349

10.  Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries.

Authors:  Piero Poletti; Alessia Melegaro; Marco Ajelli; Emanuele Del Fava; Giorgio Guzzetta; Luca Faustini; Giampaolo Scalia Tomba; Pierluigi Lopalco; Caterina Rizzo; Stefano Merler; Piero Manfredi
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

View more
  10 in total

Review 1.  Varicella vaccination - the global experience.

Authors:  Peter Wutzler; Paolo Bonanni; Margaret Burgess; Anne Gershon; Marco Aurélio Sáfadi; Giacomo Casabona
Journal:  Expert Rev Vaccines       Date:  2017-07-13       Impact factor: 5.217

2.  Exploring the Seasonal Drivers of Varicella Zoster Virus Transmission and Reactivation.

Authors:  Kevin M Bakker; Marisa C Eisenberg; Robert Woods; Micaela E Martinez
Journal:  Am J Epidemiol       Date:  2021-09-01       Impact factor: 5.363

3.  The natural history of varicella zoster virus infection in Norway: Further insights on exogenous boosting and progressive immunity to herpes zoster.

Authors:  Luigi Marangi; Grazina Mirinaviciute; Elmira Flem; Gianpaolo Scalia Tomba; Giorgio Guzzetta; Birgitte Freiesleben de Blasio; Piero Manfredi
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

4.  Evaluation of the effect of chickenpox vaccination on shingles epidemiology using agent-based modeling.

Authors:  Ellen Rafferty; Wade McDonald; Weicheng Qian; Nathaniel D Osgood; Alexander Doroshenko
Journal:  PeerJ       Date:  2018-06-20       Impact factor: 2.984

5.  Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.

Authors:  Lara J Wolfson; Vincent J Daniels; Matthew Pillsbury; Zafer Kurugöl; Cuneyt Yardimci; Jeffrey Kyle; Ener Cagri Dinleyici
Journal:  PLoS One       Date:  2019-08-13       Impact factor: 3.240

6.  Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.

Authors:  Ellen Wolff; Katarina Widgren; Gianpaolo Scalia Tomba; Adam Roth; Tiia Lep; Sören Andersson
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

7.  Age-Dependent Pre-Vaccination Immunity Affects the Immunogenicity of Varicella Zoster Vaccination in Middle-aged Adults.

Authors:  Marieke van der Heiden; Lia G H de Rond; Menno C van Zelm; Guy A M Berbers; Annemieke M H Boots; Anne-Marie Buisman
Journal:  Front Immunol       Date:  2018-01-23       Impact factor: 7.561

8.  Risk of herpes zoster after exposure to varicella to explore the exogenous boosting hypothesis: self controlled case series study using UK electronic healthcare data.

Authors:  Harriet Forbes; Ian Douglas; Adam Finn; Judith Breuer; Krishnan Bhaskaran; Liam Smeeth; Simon Packer; Sinéad M Langan; Kathryn E Mansfield; Robin Marlow; Heather Whitaker; Charlotte Warren-Gash
Journal:  BMJ       Date:  2020-01-22

9.  The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study.

Authors:  Alessia Melegaro; Valentina Marziano; Emanuele Del Fava; Piero Poletti; Marcello Tirani; Caterina Rizzo; Stefano Merler
Journal:  BMC Med       Date:  2018-07-17       Impact factor: 8.775

10.  Clinical and economic impact of universal varicella vaccination in Norway: A modeling study.

Authors:  Manjiri Pawaskar; Colleen Burgess; Mathew Pillsbury; Torbjørn Wisløff; Elmira Flem
Journal:  PLoS One       Date:  2021-07-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.